Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020

Abstract excerpt

Since the discovery of anaplastic lymphoma kinase fusion-positive (ALK) NSCLC in 2007, the methods to detect ALK NSCLC have evolved and expanded from fluorescence in situ hybridization and immunohistochemistry to next-generation DNA sequencing, targeted RNA sequencing, and whole transcriptome sequencing. As such, the deep sequencing methods have resulted in the expansion of distinct fusion partners identified in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations